West Hollywood, CA

James R Berenson, MD Inc.

Multiple Myeloma

Plasma Cell Cancer

Lenalidomide

Romidepsin

Carfilzomib

Pomalidomide

Dexamethasone

Doxorubicin

Ixazomib

Bortezomib

Oncotherapeutics

Celgene

condition

allSponsorName

Karyopharm Therapeutics

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

James R Berenson, MD Inc. | West Hollywood, CA

Site insights

Work at this site?

Active trials

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Trial sponsors